Soluble monomeric EphrinA1 is released from tumor cells and is a functional ligand for the EphA2 receptor

Area of Science:

• Molecular Biology
• Cell Biology
• Cancer Research

Background:

• EphrinA1 is a known antioncogenic ligand that typically functions as a membrane-anchored protein requiring clustering.
• Its role in glioblastoma multiforme (GBM) pathobiology involves interaction with the EphA2 receptor.

Purpose of the Study:

• To investigate the functional form of ephrinA1 in glioblastoma and breast adenocarcinoma cells.
• To determine if soluble, monomeric ephrinA1 retains biological activity.

Main Methods:

• Analysis of conditioned media from GBM and breast adenocarcinoma cells.
• Treatment of cells with soluble monomeric ephrinA1.
• Assessment of EphA2 receptor internalization and downregulation.
• Evaluation of cell morphology and Ras-MAPK pathway activity.
• Testing function in embryonic neuronal growth cone collapse assays.
• Investigation of ephrinA1 cleavage from the plasma membrane using metalloprotease inhibitors.

Main Results:

• EphrinA1 is released from cancer cells as a soluble, monomeric protein.
• Soluble monomeric ephrinA1 induces EphA2 internalization and downregulation.
• This form of ephrinA1 alters cell morphology and suppresses the Ras-MAPK pathway.
• Soluble monomeric ephrinA1 elicits neuronal growth cone collapse, demonstrating physiological function.
• EphrinA1 is proteolytically cleaved from the GBM cell plasma membrane by a metalloprotease.

Conclusions:

• EphrinA1 can function as a soluble monomer, independent of juxtacrine interactions.
• This soluble form may act in a paracrine manner on the EphA2 receptor.
• Findings have implications for understanding ephrinA1/EphA2 roles in disease and for developing ephrinA1-based therapeutics targeting EphA2.